Harry: and the stock goes down fifty cents? <VBG>; But seriously, thank you for all your contributions and insights. take care.
Neuropathic Pain Treatments Reviewed by NeuroInvestment
Tuesday September 5, 9:00 am ET
CARDIFF, CA--(MARKET WIRE)--Sep 5, 2006 -- NeuroInvestment today announced the release of its September issue, which reviews novel treatments being developed for neuropathic pain. This follows on the May 2006 review of programs addressing nociceptive and inflammatory pain. With millions of Americans suffering from neuropathic pain of varying etiologies, and a lack of a treatment that provides relief to more than a minority of patients, the search for improved analgesics and/or neuroprotective therapies has hastened -- particularly given the legacy of Neurontin's success in establishing the scale of this market. There are many programs which seek to incrementally improve upon the current armamentarium: XenoPort's prodrug strategy, the NeurogesX capsaicin patch, and the milnacipran program from Cypress Biosciences and Forest. The milnacipran program addresses a large, related, parallel indication, fibromyalgia. There is also a cornucopia of new chemical entities pursuing novel mechanisms in the hope of adding a dramatically improved range of options. Among these are programs from Neuromed and Neurogen (NASDAQ:NRGN - News) partnered with Merck; Renovis (NASDAQ:RNVS - News) partnered with Pfizer; Torrey Pines Therapeutics, Acadia Pharmaceuticals (NASDAQ:ACAD - News) partnered with both Allergan and Sepracor, Pharmos, and Trophos |
